Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Panagiotis Baliakas; Andreas Agathangelidis; Anastasia C Hadzidimitriou; Lesley-Ann Sutton; Eva Minga; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao-Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin Ekström Smedby; Lone Bredo Pedersen; Denis Moreno; Kirsten van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie-Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian Geisler; Anton Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos

doi:10.1182/blood-2014-09-600874

Back

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Journal article

Open access

Peer reviewed

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Panagiotis Baliakas, Andreas Agathangelidis, Anastasia C Hadzidimitriou, Lesley-Ann Sutton, Eva Minga, Athina Tsanousa, Lydia Scarfò, Zadie Davis, Xiao-Jie Yan, Tait Shanafelt, …

Blood, Vol.125(5), pp.856-859

29/01/2015

DOI: https://doi.org/10.1182/blood-2014-09-600874

PMCID: PMC4311230

PMID: 25634617

Abstract

Antigen

B-cell

Chronic lymphocytic leukemia

Genes

Mutation

Homogeneity

Chronic b-cell leukemias

Immunoglobulins

Receptors

Aged

Antineoplastic Agents

Male

Middle Aged

Prognosis

Somatic Hypermutation, Immunoglobulin

Survival Analysis

Time-to-Treatment

Treatment Outcome

B-Lymphocytes

Female

Gene Expression Regulation, Leukemic

Gene Rearrangement, B-Lymphocyte, Heavy Chain

Genetic Heterogeneity

Humans

Immunoglobulin Heavy Chains

Leukemia, Lymphocytic, Chronic, B-Cell

An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non–subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non–subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non–subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non–subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1182/blood-2014-09-600874View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
Creators - without role: Panagiotis Baliakas - Uppsala University
Andreas Agathangelidis - Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
Anastasia C Hadzidimitriou - Science for Life Laboratory
Lesley-Ann Sutton - Uppsala University
Eva Minga - Centre for Research and Technology Hellas
Athina Tsanousa - Aristotle University of Thessaloniki
Lydia Scarfò - Istituti di Ricovero e Cura a Carattere Scientifico
Zadie Davis - Royal Bournemouth Hospital
Xiao-Jie Yan - Feinstein Institute for Medical Research
Tait Shanafelt - Mayo Clinic in Arizona
Karla Plevova - Central European Institute of Technology – Masaryk University
Yorick Sandberg - Erasmus University Rotterdam
Fie Juhl Vojdeman - Rigshospitalet
Myriam Boudjogra - Pitié-Salpêtrière Hospital
Tatiana Tzenou - National and Kapodistrian University of Athens
Maria Chatzouli - General Hospital of Nikea
Charles Chu - Feinstein Institute for Medical Research
Silvio Veronese - Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Anne Gardiner - Royal Bournemouth Hospital
Larry Mansouri - Uppsala University
Karin Ekström Smedby - Karolinska Institutet
Lone Bredo Pedersen - Rigshospitalet
Denis Moreno - Université de Montpellier, Institut de Génétique Humaine - IGH
Kirsten van Lom - Erasmus MC
Véronique Giudicelli - Université de Montpellier, Institut de Génétique Humaine - IGH
Hana Skuhrova Francova - University Hospital Brno
Florence Nguyen-Khac - Sorbonne Université
Panagiotis Panagiotidis - National and Kapodistrian University of Athens
Gunnar Juliusson - Lund University
Lefteris Angelis - Aristotle University of Thessaloniki
Achilles Anagnostopoulos - George Institute for Global Health
Marie-Paule Lefranc - Université de Montpellier, Institut de Génétique Humaine - IGH
Monica Facco - Veneto Institute of Molecular Medicine
Livio Trentin - University of Padua
Mark Catherwood - University of Ulster
Marco Montillo - Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Christian Geisler - Rigshospitalet
Anton Langerak - Erasmus University Rotterdam
Sarka Pospisilova - Central European Institute of Technology
Nicholas Chiorazzi - Feinstein Institute for Medical Research
David Oscier - Royal Bournemouth Hospital
Diane Jelinek - Mayo Clinic in Arizona
Nikos Darzentas - Central European Institute of Technology
Chrysoula Belessi - General Hospital of Nikea
Frederic Davi - Sorbonne Université
Paolo Ghia - Istituti di Ricovero e Cura a Carattere Scientifico
Richard Rosenquist - Uppsala University
Kostas Stamatopoulos - Karolinska Institutet
Publication Details: Blood, Vol.125(5), pp.856-859
Identifiers: 9938342009311
Academic Unit: Institut de Génétique Humaine - IGH
Language: English
Resource Type: Journal article
Local Fields: hal-01265855